e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 11, 2010 (February 11, 2010)
 
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
         
Florida
(State or other jurisdiction
of incorporation) 		  000-33357
(Commission File Number) 		  65-0643773
(IRS Employer
Identification No.)
     
2 Snunit Street
Science Park, POB 455
Carmiel, Israel
(Address of principal executive offices) 		  20100
(Zip Code)
Registrant’s telephone number, including area code +972-4-988-9488
(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01. Other Events
On February 11, 2010, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that additional data from the Company’s pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled “Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) — taliglucerase alfa.” The oral presentation was made by Hanna Rosenbaum M.D., Director of Hematology Day Care Unit, RAMBAM Medical Center, Haifa, Israel, and study investigator. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d)   Exhibits
99.1   Press release dated February 11, 2010.

2

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
         
  PROTALIX BIOTHERAPEUTICS, INC.
 		  
Date: February 11, 2010  By:   /s/ David Aviezer    
    Name:   David Aviezer, Ph.D.   
    Title:   President and Chief Executive Officer   
 

3